^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
Excerpt:
...Biopsy tissues with IHC indicates deficient mismatch repair(dMMR),that is,the loss of at least one of the four proteins ,MSH1,MSH2,MSH6,PMS2;or gene detection implies MSI-H; 3....
Trial ID:
Source:
Title:
Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer
Excerpt:
...Tumor tissues were identified as mismatch repair-deficient (dMMR) by immunohistochemistry (IHC) method or microsatellite instability-high (MSI-H) by polymerase chain reaction (PCR)....
Trial ID:
More C2 evidence
Source:
Title:
Triplezumab Combined With CAPEOX Regimen in Neoadjuvant Therapy for Locally Advanced Colon Cancer
Excerpt:
...Pathological diagnosis of msi-h /dMMR colon cancer....
Trial ID:
Source:
Title:
A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal Cancer
Excerpt:
...- Histologically confirmed advanced or recurrent colorectal cancer, and MSI detection identified MSI-H;...
Trial ID:
Source:
Title:
A phase 2 study for PD-1 antibody JS001 in Participants With Microsatellite Instability-High (MSI-H) advanced or recurrent colorectal cancer
Excerpt:
...Histologically confirmed advanced or recurrent colorectal cancer, and MSI detection identified MSI-H; 3. ...
Trial ID:
Less C2 evidence
Source:
Title:
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial
Published date:
10/21/2021
Excerpt:
15 of 17 patients (88% [95% CI 64–99]) in the toripalimab plus celecoxib group and 11 of 17 patients (65% [38–86]) in the toripalimab monotherapy group had a pathological complete response...Neoadjuvant toripalimab with or without celecoxib could be a potential therapeutic option for patients with mismatch repair deficient or microsatellite instability-high, locally advanced, colorectal cancer. This treatment was associated with a high pathological complete response rate...
DOI:
https://doi.org/10.1016/S2468-1253(21)00348-4
Trial ID:
